Pinealon: Scientific Profile

Publicado el 12 de julio de 2026 · Actualizado el 28 de agosto de 2026

Pinealon is a short synthetic tripeptide (Glu-Asp-Arg, EDR; CAS 175175-23-2) from the Khavinson family of peptide bioregulators, proposed as a neuroprotective peptide for research. Its hypothetical mechanism is epigenetic-regulatory of gene expression in neuronal tissue. The available evidence is limited and comes mostly from a single research group in preclinical models.

Pinealon is a synthetic tripeptide of the sequence Glu-Asp-Arg (abbreviated EDR), registered with the CAS number 175175-23-2, molecular formula C15H26N6O8, and a molecular weight of approximately 418.41 g/mol. It belongs to the class of the so-called short peptide bioregulators developed by the group of the Russian researcher Vladimir Khavinson and collaborators at the Institute of Bioregulation and Gerontology in St. Petersburg. These compounds are oligopeptides of two to four amino acids that were designed from the fractionation of tissue extracts; in the case of Pinealon, the conceptual framework associates it with peptides derived from brain and pineal tissue, and it is therefore classified within the anti-aging and neuro-oriented category within this body of work. It is important to frame everything that follows as material intended exclusively for research: the claims about its activity come from laboratory studies and experimental models, not from an approved clinical use.

From a structural standpoint, Pinealon is an extremely simple peptide: three residues (glutamic acid, aspartic acid, and arginine) joined by peptide bonds. This brevity is central to the mechanistic hypothesis proposed by the Khavinson group: tripeptides of this size would be small enough to cross cell membranes and, according to the proposed models, reach the nucleus, where they are posited to interact with specific regions of DNA. The combination of a basic residue (arginine, positively charged) with two acidic residues generates an amphoteric peptide whose charge distribution has been used to argue for a possible affinity for DNA grooves or for histones. It should be emphasized that these are proposed mechanistic models and not an established consensus of the independent literature.

The mechanism of action attributed to Pinealon is, therefore, of an epigenetic or gene-expression-regulating type. The working hypothesis holds that the tripeptide would modulate the transcription of genes involved in redox homeostasis, neuronal survival, and the response to oxidative stress, theoretically favoring the synthesis of proteins associated with cellular protection. In experimental models published by this group, its effect on apoptosis markers, on the activity of antioxidant enzymes, and on neuronal viability under conditions of hypoxia or hyperhomocysteinemia has been explored. These findings have been described mainly in cell cultures and in animal models (for example, rodents exposed to prenatal stress or to hypoxia), and serve as the basis for its informal designation as a "neuroprotective peptide" within research in this line. Nevertheless, the translation of these results to any human context is not established.

The documented research applications are concentrated in experimental neuroscience and in aging models. Pinealon has been used as a tool to study mechanisms of neuroprotection against oxidative stress, to explore the modulation of gene expression by short peptides, and to investigate possible effects on cognitive functions in animal models of impairment. Within Khavinson's broader bioregulator program, it is usually studied alongside other related tripeptides such as Cortagen or Cartalax in experimental batteries oriented toward the central nervous system. In all these cases, the compound functions as a research reagent, not as a therapeutic agent.

As for the level of evidence, it is essential to be honest and explicit: the published database on Pinealon is limited and comes for the most part from a single research group (Khavinson and colleagues) and associated publications. There is no robust body of independent clinical trials, replicated by different laboratories, that confirm the proposed effects in humans. Much of the literature is preclinical (in vitro and in animal models) or of a mechanistic-theoretical nature. For this reason, the assigned level of evidence is "limited", and any interpretation of the data must be made with methodological caution, avoiding extrapolations. The family of short peptide bioregulators has generated interest in experimental gerontology, but also criticism for the scarcity of external validation and the small size of many of the studies. A researcher working with this compound should consider these limitations when designing controls, interpreting results and comparing with the available literature.

Regarding its laboratory handling properties, Pinealon is a short peptide that is usually supplied in lyophilized form. As with most peptides, the lyophilized form is relatively stable when cold and dry, whereas reconstituted solutions are more labile and must be protected from elevated temperature, repeated freeze-thaw cycles and, as a prudent practice, from direct light. Typical reconstitution in research settings is carried out with bacteriostatic water or with buffer solutions appropriate to the assay. These are preservation considerations for an experimental laboratory reagent. In summary, Pinealon is a short bioregulator tripeptide of interest in experimental neuroscience and aging research, with a proposed epigenetic mechanism but an evidence base that is still limited and dependent on a small research group.